16. CNAG - National Genome Analysis Centre

MUNICIPALITY
Barcelona

HEADING
The CNAG is expanding its participation in two new projects of the International Cancer Genome Consortium and is becoming consolidated as a European centre of reference in sequencing and analysis.

ECONOMIC AND TECHNICAL DETAILS
- Budget: €3.75 M
- Sources of finance: State Administration (MINECO), Government of Catalonia (Ministries of Health and Economy and Knowledge), competitive public projects and contracts with companies, universities and research centres
- Installations: 12 state-of-the-art sets of sequencing equipment and a powerful cluster with over 900 computation nodes
- Personnel: 50 employees

PROJECT DESCRIPTION
The CNAG has become consolidated as a key actor in the national biomedical cluster, offering its different research groups a first-class scientific infrastructure.

The CNAG has continued with its mission of furthering the success of Spanish participation in the International Cancer Genome Consortium, through the CLL (chronic lymphocytic leukaemia) project led by Dr. Elías Campo, of Hospital Clínic. Furthermore, it has extended its participation in this consortium and become involved in the sequencing and analysis of prostate cancer and Ewing's sarcoma, two projects initiated by the French.

The CNAG has also taken part in fifteen projects, most of them European and competitively funded. Apart from that, it has collaborated with sixty-five research centres, private companies, hospitals and universities (fifty of which are new customers), which has permitted it to achieve a turnover of over two million euros.

At present, the CNAG offers a broad range of genomic applications that include the *de novo* sequencing or re-sequencing of whole genomes, the re-sequencing of exomes or specific regions, the identification of DNA binding sites and the sequencing of RNA.

For 2013, the CNAG will continue supporting all research centres, universities, hospitals and private companies that wish to carry out sequencing projects in areas as diverse as cancer, rare diseases, the preservation of endangered species and the improvement of species of agricultural interest.

The CNAG will continue to develop new laboratory methods and to invest in its sequencing and analysis platform, so as to place the most advanced technology in the area at the service of the scientific community.

PROJECT ADDRESS
www.cnag.cat

RESPONSIBLE
Ivo Gut, Director, CNAG